Investigating the requirements for the ISO 19152 LADM survey encodings

The ISO 19152:2012 Land Administration Domain Model (LADM), focuses on standardised modelling of land information at the conceptual level, and together with LADM’s three main packages, it has a dedicated sub package for Spatial and Surveying representation. The first edition of the standard provides multiple spatial representations, and a rather generic survey model based on the ISO 19156:2011 Observations and Measurement Standard (O&M). As an ISO standard, the LADM is subject to periodic revision, and currently, its revision is ongoing and among other refinements, the enhanced support of the surveying model, both at conceptual and implementation level is expected. In this scene, in order for LADM to support a broad range in surveying and data acquisition approaches and accuracies, a refinement is ongoing considering the recent evolution of technology and the encodings used in practice. Therefore, a refined survey model has been prepared and is included at the New Working Item Proposal for LADM Edition II – Part 2, with various data acquisition techniques, as presented in this paper. Based on it and on the experience and requirements from the industry and the standardization organisations, this paper presents the requirements that encoding formats should fulfill to support the revised surveying model

Investigating the Requirements for the ISO 19152 LADM Survey Encodings

The ISO 19152:2012 Land Administration Domain Model (LADM), focuses on standardised modelling of land information at the conceptual level, and together with LADM’s three main packages, it has a dedicated sub package for Spatial and Surveying representation. The first edition of the standard provides multiple spatial representations, and a rather generic survey model based on the ISO 19156:2011 Observations and Measurement Standard (O&M). As an ISO standard, the LADM is subject to periodic revision, and currently, its revision is ongoing and among other refinements, the enhanced support of the surveying model, both at conceptual and implementation level is expected. In this scene, in order for LADM to support a broad range in surveying and data acquisition approaches and accuracies, a refinement is ongoing considering the recent evolution of technology and the encodings used in practice. Therefore, a refined survey model has been prepared and is included at the New Working Item Proposal for LADM Edition II – Part 2, with various data acquisition techniques, as presented in this paper. Based on it and on the experience and requirements from the industry and the standardization organisations, this paper presents the requirements that encoding formats should fulfill to support the revised surveying model.GIS Technologi

X-Ray topographic observations of slip distributions in alpha silicon carbide /

An x-ray topographic study is made of three hexagonal SiC crystals, type 6H, of different national origin. All three crystals exhibit a high density of dislocations, many originating at the nucleation edge of the crystal and fanning out to the crystal boundaries. Burgers vectors were identified. Slip in the (1,1,-2,0) direction, characteristic of hexagonal materials, was observed. (Author).Research supported by the Air Force Cambridge Research Laboratories, Air Force Systems Command, United States Air Force, L.G. Hanscom Field, Bedford, Massachusetts.Solid State Sciences Laboratory Project 5620.AD0744076 (from http://www.dtic.mil)."30 March 1972."Includes bibliographical references (page 13).An x-ray topographic study is made of three hexagonal SiC crystals, type 6H, of different national origin. All three crystals exhibit a high density of dislocations, many originating at the nucleation edge of the crystal and fanning out to the crystal boundaries. Burgers vectors were identified. Slip in the (1,1,-2,0) direction, characteristic of hexagonal materials, was observed. (Author).Mode of access: Internet

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics